Cargando…

FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC)

Background. FGFR1/2/3 fusions have been reported infrequently in aNSCLC, including as a rare, acquired resistance mechanism following treatment with EGFR TKIs. Data regarding their prevalence and therapeutic implications are limited. Methods. The Guardant Health (GH) electronic database (ED) was eva...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raphael, Ari, Dudnik, Elizabeth, Hershkovitz, Dov, Jain, Suyog, Olsen, Steve, Soussan-Gutman, Lior, Ben-Shitrit, Taly, Dvir, Addie, Nechushtan, Hovav, Peled, Nir, Onn, Amir, Agbarya, Abed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9102087/ https://www.ncbi.nlm.nih.gov/pubmed/35566609 http://dx.doi.org/10.3390/jcm11092475

Ejemplares similares

The Impact of Comprehensive Genomic Profiling (CGP) on the Decision-Making Process in the Treatment of ALK-Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2(nd)/3(rd)-Generation ALK Tyrosine Kinase Inhibitors (TKIs)
por: Raphael, Ari, et al.
Publicado: (2022)

Liquid First Is “Solid” in Naïve Non-Small Cell Lung Cancer Patients: Faster Turnaround Time With High Concordance to Solid Next-Generation Sequencing
por: Sehayek, Or, et al.
Publicado: (2022)

Hormone dependent metastatic salivary gland carcinoma: a case report
por: Agbarya, Abed, et al.
Publicado: (2014)

Long term follow-up of EGFR mutated NSCLC cases
por: Rennert, Gad, et al.
Publicado: (2020)

Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases
por: Goldstein, Iris M, et al.
Publicado: (2020)

Metastatic Salivary Gland Tumors: A Single-Center Study Demonstrating the Feasibility and Potential Clinical Benefit of Molecular-Profiling-Guided Therapy
por: Popovtzer, Aron, et al.
Publicado: (2015)

New ARCHITECT plasma pro-gastrin-releasing peptide assay for diagnosing and monitoring small-cell lung cancer
por: Nisman, Benjamin, et al.
Publicado: (2016)

Molecular Profiling-Selected Therapy for Treatment of Advanced Pancreaticobiliary Cancer: A Retrospective Multicenter Study
por: Epelbaum, Ron, et al.
Publicado: (2015)

Not only for melanoma. Subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab: A case report
por: Sarfaty, Michal, et al.
Publicado: (2017)

Tumor PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced NSCLC patients
por: Horesh, Adi, et al.
Publicado: (2023)

Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study
por: Peled, Nir, et al.
Publicado: (2021)

Effects of the single nucleotide polymorphism at MDM2 309 on breast cancer patients with/without BRCA1/2 mutations
por: Nechushtan, Hovav, et al.
Publicado: (2009)

Health and Budget Impact of Liquid-Biopsy-Based Comprehensive Genomic Profile (CGP) Testing in Tissue-Limited Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients
por: Patel, Yuti P., et al.
Publicado: (2021)

Role of Nudt2 in Anchorage-Independent Growth and Cell Migration of Human Melanoma
por: Hidmi, Sana’, et al.
Publicado: (2023)

Biomarker-Driven Therapy in Metastatic Gastric and Esophageal Cancer: Real-Life Clinical Experience
por: Purim, Ofer, et al.
Publicado: (2018)

Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data
por: Dudnik, Elizabeth, et al.
Publicado: (2021)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen, Miaomiao, et al.
Publicado: (2018)

Clinical Impact of Adherence to NCCN Guidelines for Biomarker Testing and First-Line Treatment in Advanced Non-Small Cell Lung Cancer (aNSCLC) Using Real-World Electronic Health Record Data
por: John, Ani, et al.
Publicado: (2021)

ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data
por: Moskovitz, Mor, et al.
Publicado: (2022)

Multi-Center Real-World Outcomes of Nivolumab Plus Ipilimumab and Chemotherapy in Patients with Metastatic Non-Small-Cell Lung Cancer
por: Shalata, Walid, et al.
Publicado: (2023)

SCLC, Paraneoplastic Dermatomyositis, Positive Transcription Intermediary Factor 1-γ, and Point Mutation in the Transcription Intermediary Factor 1-γ Coding Gene: A Case Report
por: Arnon, Johnathan, et al.
Publicado: (2021)

Can Ipilimumab restore immune response in advanced NSCLC after progression on anti‐PD‐1/PD‐L1 agents?
por: Sternschuss, Michal, et al.
Publicado: (2020)

Systems assessment of intercalated combination of chemotherapy and EGFR TKIs versus chemotherapy or EGFR TKIs alone in advanced NSCLC patients
por: Yan, Han, et al.
Publicado: (2015)

Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations
por: Wei, Zhigang, et al.
Publicado: (2017)

Review of EGFR TKIs in Metastatic NSCLC, Including Ongoing Trials
por: Melosky, Barbara
Publicado: (2014)

Nivolumab in Non-Small Cell Lung Cancer: Real World Long-Term Survival Results and Blood-Based Efficacy Biomarkers
por: Daher, Sameh, et al.
Publicado: (2021)

Clinical outcomes of WBRT plus EGFR-TKIs versus WBRT or TKIs alone for the treatment of cerebral metastatic NSCLC patients: a meta-analysis
por: Zheng, Hong, et al.
Publicado: (2017)

Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC
por: Wu, Xuan, et al.
Publicado: (2013)

Bevacizumab Combined with Continuation of EGFR-TKIs in NSCLC Beyond Gradual Progression
por: Xu, Ziyi, et al.
Publicado: (2022)

Editorial: Challenges and opportunities of TKIs in the treatment of NSCLC patients with uncommon mutations
por: Su, Chunxia, et al.
Publicado: (2022)

Lung Cancer in Young Patients: Higher Rate of Driver Mutations and Brain Involvement, but Better Survival
por: Suidan, Anna May, et al.
Publicado: (2019)

BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors
por: Dudnik, Elizabeth, et al.
Publicado: (2021)

Is Elevation of Alkaline Phosphatase a Predictive Factor of Response to Alectinib in NSCLC?
por: Shalata, Walid, et al.
Publicado: (2021)

Programmed death-ligand 1 expression discrepancy between primary tumor and metastatic lymph nodes in non-small cell lung cancer
por: Kian, Waleed, et al.
Publicado: (2020)

Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC: a retrospective chart review (REFLECT)
por: Addeo, Alfredo, et al.
Publicado: (2021)

Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance
por: Wu, Wen-Shuo, et al.
Publicado: (2014)

Inhibition of Tumor Lymphangiogenesis is an Important Part that EGFR-TKIs Play in the Treatment of NSCLC
por: Zhang, Yan, et al.
Publicado: (2020)

First line Immunotherapy for Non-Small Cell Lung Cancer
por: Nasser, Nicola J., et al.
Publicado: (2020)

Potential Mechanisms of Cancer-Related Hypercoagulability
por: Nasser, Nicola J., et al.
Publicado: (2020)

Adjuvant Treatment with Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor Mutated Non-Small-Cell Lung Carcinoma Patients, Past, Present and Future
por: Shalata, Walid, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jn0gtrtvte111mqlv2ekttqagv